Reliability and minimal clinically important differences of forced vital capacity: Results from the Scleroderma Lung Studies (SLS-I and SLS-II)

Autor: Suzanne Kafaja, Philip J. Clements, Holly Wilhalme, Chi-hong Tseng, Daniel E. Furst, Grace Hyun Kim, Jonathan Goldin, Elizabeth R. Volkmann, Michael D. Roth, Donald P. Tashkin, Dinesh Khanna, Ann Arbor, D. Khanna, Los Angeles, P. J. Clements, D. P. Tashkin, R. Elashoff, J. Goldin, M. Roth, D. Furst, K. Bulpitt, W.-L. J. Chung, S. Viasco, M. Sterz, L. Woolcock, X. Yan, J. Ho, S. Vasunilashorn, I. da Costa, J. R. Seibold, D. J. Riley, J. K. Amorosa, V. M. Hsu, D. A. McCloskey, J. E. Wilson, J. Varga, D. Schraufnagel, A. Wilbur, D. Lapota, S. Arami, P. Cole-Saffold, R. Simms, A. Theodore, P. Clarke, J. Korn, K. Tobin, M. Nuite, R. Silver, M. Bolster, C. Strange, S. Schabel, E. Smith, J. Arnold, K. Caldwell, M. Bonner, R. Wise, F. Wigley, B. White, L. Hummers, M. Bohlman, A. Polito, G. Leatherman, E. Forbes, M. Daniel, V. Steen, C. Read, C. Cooper, S. Wheaton, A. Carey, A. Ortiz, M. Mayes, E. Parsley, S. Oldham, T. Filemon, S. Jordan, M. Perry, null K. Connolly, J. Golden, P. Wolters, R. Webb, J. Davis, C. Antolos, C. Maynetto, B. Fessler, M. Olman, C. Sanders, L. Heck, T. Parkhill, N. Rothfield, M. Metersky, R. Cobb, M. Aberles, F. Ingenito, E. Breen, K. Mubarak, J. L. Granda, J. Silva, Z. Injic, R. Alexander, S. Springmeyer, S. Kirkland, J. Molitor, R. Hinke, A. Mondt, T. Thompson, S. Rounds, M. Weinstein, B. Thompson, H. Paulus, S. Levy, D. Martin, E. Kissin, F. Y. Cheong, G. Marlis, J. Mason-Berry, P. Saffold, M. Rodriguez, L. Guzman, J. Brook, G. Ibrahim, K. Largaespada, C. Fridley, M. Zulmastashvili, A. Manu, S. Moore, F. N. Hant, K. Gibson, M. Morrison, H. Donnelly, C. Marlin, J. Gangar, A. Eller, D. Leong, M. Lalosh, J. Obata, D. Franklin, E. Schiopu, M. Benedict-Blue, V. Leone, J. Shaw, F. Tan, J. Anderson, A. Saulino, P. Carey, M. Esplin, P. Carlson

Publikováno v: American journal of respiratory and critical care medicine. 197(5)

Rationale: FVC percent predicted (FVC%) is the primary outcome measure in clinical trials of systemic sclerosis interstitial lung disease. For interpretation of change in the FVC% over time, it is important to define whether these changes are clinica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85f4196559588eeaa282cfc49e0fb9be
https://pubmed.ncbi.nlm.nih.gov/29186664

Recognition of pulmonary hypertension in the rheumatology community: lessons from a Quality Enhancement Research Initiative

Autor: D, Khanna, Ma, Tan, D E, Furst, N S, Hill, V V, McLaughlin, R M, Silver, V D, Steen, A, Langer, J R, Seibold, Barbara, Segal

Publikováno v: Clinical and experimental rheumatology. 32(6 Suppl 86)

The aim of this study was to utilise the Quality Enhancement Research Initiative in Systemic Sclerosis (QuERI-SSc) to measure and reduce a perceived gap in the diagnosis of pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::dd0854529d02e6e15a51dadcc8c030e6
https://pubmed.ncbi.nlm.nih.gov/24295227

A path to the future in scleroderma

Autor: J. R. Seibold, Marco Matucci-Cerinic, Ulf Müller-Ladner, Oliver Distler

In October of 2007, a group of true experts in diverse areas relevant to scleroderma were invited to Florence, Italy for a 2-day symposium on ‘Controversies in Scleroderma’. As the organizing committee for this activity, we selected the topics an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46f3fa8fb6459ed7f294509a4182af68
https://www.zora.uzh.ch/id/eprint/154781/

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

Autor: J E, Pope, N, Bellamy, J R, Seibold, M, Baron, M, Ellman, S, Carette, C D, Smith, I M, Chalmers, P, Hong, D, O'Hanlon, E, Kaminska, J, Markland, J, Sibley, L, Catoggio, D E, Furst

Publikováno v: Arthritis and rheumatism. 44(6)

Early diffuse scleroderma (systemic sclerosis; SSc) has no proven treatment. This study was undertaken to examine the efficacy of methotrexate (MTX) in improving the skin and other disease parameters in early diffuse SSc.Seventy-one patients with dif

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5c3a80a225621066fce9aa3f749683d7
https://pubmed.ncbi.nlm.nih.gov/11920427

Safety and pharmacokinetics of recombinant human relaxin in systemic sclerosis

Autor: J R, Seibold, P J, Clements, D E, Furst, M D, Mayes, D A, McCloskey, L W, Moreland, B, White, F M, Wigley, S, Rocco, M, Erikson, J F, Hannigan, M E, Sanders, E P, Amento

Publikováno v: The Journal of rheumatology. 25(2)

To investigate the safety and pharmacokinetics of a 28 day continuous subcutaneous infusion of recombinant human relaxin in patients with systemic sclerosis with diffuse scleroderma.Thirty patients with stable diffuse scleroderma of moderate severity

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0f0679cc335e59425dc7bfbf5d40bf79
https://pubmed.ncbi.nlm.nih.gov/9489823